Yuichiro Nakano

Treatment with risperidone for 4 weeks increased plasma 3-methoxy-4-hydroxypnenylglycol (MHPG) levels, but did not alter plasma brain-derived neurotrophic factor (BDNF) levels in schizophrenic patients

Reiji Yoshimura, Hikaru Hori, Nobuhisa Ueda et al. · Progress in Neuro-Psychopharmacology and Biological Psychiatry · 2007 · 56 citations

Medicine, Pharmacology, Psychiatry +10

Effect of risperidone on plasma catecholamine metabolites and brain‐derived neurotrophic factor in patients with bipolar disorders

Reiji Yoshimura, Yuichiro Nakano, Hikaru Hori et al. · Human Psychopharmacology Clinical and Experimental · 2006 · 51 citations

Pharmacy, Pharmacotherapy, Psychiatry +14

Association between plasma nitric oxide metabolites levels and negative symptoms of schizophrenia: a pilot study

Yuichiro Nakano, Reiji Yoshimura, Hideki Nakano et al. · Human Psychopharmacology Clinical and Experimental · 2010 · 40 citations

Medicine, Pharmacology, Psychiatry +16

Peroxisome proliferator-activated receptor alpha agonist suppresses neovascularization by reducing both vascular endothelial growth factor and angiopoietin-2 in corneal alkali burn

Takeshi Arima, Masaaki Uchiyama, Yuichiro Nakano et al. · Scientific Reports · 2017 · 40 citations · Full text

Medicine, Ophthalmology, Pharmacology +17

PPARα Agonist Suppresses Inflammation after Corneal Alkali Burn by Suppressing Proinflammatory Cytokines, MCP-1, and Nuclear Translocation of NF-κB

Yuichiro Nakano, Masaaki Uchiyama, Takeshi Arima et al. · Molecules · 2018 · 29 citations · Full text

Life Sciences, Immunology, Pharmacology +17